| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shannon E Hill, Abigail R Esquivel, Santiago Rodriguez Ospina, Lauren M Rahal, Chad A Dickey, Laura J Blai. Chaperoning activity of the cyclophilin family prevents tau aggregation. Protein science : a publication of the Protein Society. vol 31. issue 11. 2022-10-28. PMID:36305768. |
tauopathies, such as alzheimer's disease, are characterized by the misfolding and progressive accumulation of the microtubule associated protein tau. |
2022-10-28 |
2023-08-14 |
Not clear |
| Marina Arcaro, Chiara Fenoglio, Maria Serpente, Andrea Arighi, Giorgio G Fumagalli, Luca Sacchi, Stefano Floro, Marianna D'Anca, Federica Sorrentino, Caterina Visconte, Alberto Perego, Elio Scarpini, Daniela Galimbert. A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer's Disease. Biomedicines. vol 10. issue 10. 2022-10-27. PMID:36289929. |
a novel automated chemiluminescence method for detecting cerebrospinal fluid amyloid-beta 1-42 and 1-40, total tau and phosphorylated-tau: implications for improving diagnostic performance in alzheimer's disease. |
2022-10-27 |
2023-08-14 |
Not clear |
| Marina Arcaro, Chiara Fenoglio, Maria Serpente, Andrea Arighi, Giorgio G Fumagalli, Luca Sacchi, Stefano Floro, Marianna D'Anca, Federica Sorrentino, Caterina Visconte, Alberto Perego, Elio Scarpini, Daniela Galimbert. A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer's Disease. Biomedicines. vol 10. issue 10. 2022-10-27. PMID:36289929. |
recently, a fully automated instrument for the detection of the cerebrospinal fluid (csf) biomarker for alzheimer's disease (ad) (low concentration of amyloid-beta 42 (aβ42), high concentration of total tau (t-tau) and phosphorylated-tau (p-tau181)), has been implemented, namely cleia. |
2022-10-27 |
2023-08-14 |
Not clear |
| Zizhao Ju, Zhuoyuan Li, Jiaying Lu, Fangyang Jiao, Huamei Lin, Weiqi Bao, Ming Li, Ping Wu, Yihui Guan, Qianhua Zhao, Huiwei Zhang, Jiehui Jiang, Chuantao Zu. In Vivo Tau Burden Is Associated with Abnormal Brain Functional Connectivity in Alzheimer's Disease: A Brain sciences. vol 12. issue 10. 2022-10-27. PMID:36291289. |
in vivo tau burden is associated with abnormal brain functional connectivity in alzheimer's disease: a |
2022-10-27 |
2023-08-14 |
Not clear |
| Thalia T Dimopoulos, Stephen L P Lippi, Jorge Fernandez Davila, Rachel E Barkey, Erin N Doherty, Jane M Flin. White Button Mushroom ( Brain sciences. vol 12. issue 10. 2022-10-27. PMID:36291298. |
white button mushroom ( alzheimer's disease (ad) is characterized by cognitive impairment and the presence of amyloid-β (aβ) plaques and tau tangles. |
2022-10-27 |
2023-08-14 |
mouse |
| Rosalia Bruno, Laura Pirisinu, Geraldina Riccardi, Claudia D'Agostino, Elena De Cecco, Giuseppe Legname, Franco Cardone, Pierluigi Gambetti, Romolo Nonno, Umberto Agrimi, Michele Angelo Di Bar. Gerstmann-Sträussler-Scheinker Disease with F198S Mutation Induces Independent Tau and Prion Protein Pathologies in Bank Voles. Biomolecules. vol 12. issue 10. 2022-10-27. PMID:36291746. |
here we investigated: (i) the transmissibility of gss-f198s prions to voles carrying methionine at codon 109 (bvm); (ii) the induction of hyperphosphorylated tau (ptau) in two vole lines, and (iii) compared the phenotype of gss-f198s-induced ptau with ptau induced in bvm following intracerebral inoculation of a familial alzheimer's disease case carrying presenilin 1 mutation (fad-ps1). |
2022-10-27 |
2023-08-14 |
Not clear |
| Elisabeth Kapaki, Foteini Boufidou, Mara Bourbouli, Efstratios-Stylianos Pyrgelis, Vasilios C Constantinides, Cleo Anastassopoulou, George P Paraskeva. Cerebrospinal Fluid Biomarker Profile in TDP-43-Related Genetic Frontotemporal Dementia. Journal of personalized medicine. vol 12. issue 10. 2022-10-27. PMID:36294886. |
cerebrospinal fluid (csf) biomarkers, namely total tau, phospho-tau and amyloid beta peptides, have received much attention specifically regarding alzheimer's disease (ad), since they can detect the biochemical fingerprint of ad and serve as a diagnostic tool for accurate and early diagnosis during life. |
2022-10-27 |
2023-08-14 |
Not clear |
| Carolyn Tallon, Benjamin J Bell, Anjali Sharma, Arindom Pal, Medhinee M Malvankar, Ajit G Thomas, Seung-Wan Yoo, Kristen R Hollinger, Kaleem Coleman, Elizabeth L Wilkinson, Sujatha Kannan, Norman J Haughey, Rangaramanujam M Kannan, Rana Rais, Barbara S Slushe. Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice. Pharmaceutics. vol 14. issue 10. 2022-10-27. PMID:36297501. |
alzheimer's disease (ad) is characterized by the progressive accumulation of amyloid-β and hyperphosphorylated tau (ptau), which can spread throughout the brain via extracellular vesicles (evs). |
2022-10-27 |
2023-08-14 |
mouse |
| Gunel Ayyubov. Dysfunctional microglia and tau pathology in Alzheimer's disease. Reviews in the neurosciences. 2022-10-27. PMID:36302379. |
dysfunctional microglia and tau pathology in alzheimer's disease. |
2022-10-27 |
2023-08-14 |
human |
| Pai-Yi Chiu, Fu-Chi Yang, Ming-Jang Chiu, Wei-Che Lin, Cheng-Hsien Lu, Shieh-Yueh Yan. Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia. Scientific reports. vol 12. issue 1. 2022-10-26. PMID:36289355. |
amyloid plaques and tau tangles are pathological hallmarks of alzheimer's disease (ad). |
2022-10-26 |
2023-08-14 |
human |
| C M Wischik, P Bentham, S Gauthier, S Miller, K Kook, B O Schelte. Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. The journal of prevention of Alzheimer's disease. vol 9. issue 4. 2022-10-25. PMID:36281683. |
oral tau aggregation inhibitor for alzheimer's disease: design, progress and basis for selection of the 16 mg/day dose in a phase 3, randomized, placebo-controlled trial of hydromethylthionine mesylate. |
2022-10-25 |
2023-08-14 |
Not clear |
| C M Wischik, P Bentham, S Gauthier, S Miller, K Kook, B O Schelte. Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. The journal of prevention of Alzheimer's disease. vol 9. issue 4. 2022-10-25. PMID:36281683. |
hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed phase 3 trials in mild/moderate alzheimer's disease (ad). |
2022-10-25 |
2023-08-14 |
Not clear |
| Kaitlin M Stouffer, Zhenzhen Wang, Eileen Xu, Karl Lee, Paige Lee, Michael I Miller, Daniel J Twar. From Picoscale Pathology to Decascale Disease: Image Registration with a Scattering Transform and Varifolds for Manipulating Multiscale Data. Multimodal learning for clinical decision support : 11th International Workshop, ML-CDS 2021, held in conjunction with MICCAI 2021, Strasbourg, France, October 1, 2021, Proceedings. ML-CDS (Workshop) (11th : 2021 : Online). vol 13050. 2022-10-25. PMID:36283001. |
we use our methods to quantify microscopic tau pathology across macroscopic 3d regions of the medial temporal lobe to address a major challenge in the diagnosis of alzheimer's disease-the reliance on invasive methods to detect microscopic pathology. |
2022-10-25 |
2023-08-14 |
Not clear |
| Tianxin Xie, Yuying Li, Chuan Tian, Chang Yuan, Bin Dai, Shubo Wang, Kaixiang Zhou, Jiaqi Liu, Hongwei Tan, Yi Liang, Jiapei Dai, Baian Chen, Mengchao Cu. Fused Cycloheptatriene-BODIPY Is a High-Performance Near-Infrared Probe to Image Tau Tangles. Journal of medicinal chemistry. 2022-10-25. PMID:36283122. |
neurofibrillary tangles (nfts), which are composed of abnormally hyperphosphorylated tau, are one of the main pathologic hallmarks of alzheimer's disease and other tauopathies. |
2022-10-25 |
2023-08-14 |
Not clear |
| Javier Andrés Muñiz, Carolina Lucía Facal, Leandro Urrutia, Ramiro Clerici-Delville, Ana Damianich, Juan E Ferrario, Germán Falasco, María Elena Aval. SMaRT modulation of tau isoforms rescues cognitive and motor impairments in a preclinical model of tauopathy. Frontiers in bioengineering and biotechnology. vol 10. 2022-10-24. PMID:36277399. |
abnormal tau metabolism leads to neurodegenerative diseases named tauopathies, such as alzheimer's disease and frontotemporal dementia. |
2022-10-24 |
2023-08-14 |
human |
| Julia J Segura-Uribe, Paola Garcia-de la Torre, Tzayaka Castillo-Mendieta, Iván Bribiesca-Cruz, Sandra Orozco-Suárez, Marvin Soriano-Ursúa, Rodolfo Pinto-Almazán, Claudia Fuentes-Venado, Christian Guerra-Araiz. Tibolone Improves Memory and Decreases the Content of Amyloid-β Peptides and Tau Protein in the Hippocampus of a Mice Model of Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2022-10-24. PMID:36278346. |
tibolone improves memory and decreases the content of amyloid-β peptides and tau protein in the hippocampus of a mice model of alzheimer's disease. |
2022-10-24 |
2023-08-14 |
mouse |
| Ankur Kumar, Bhupender Nehra, Dilpreet Singh, Dileep Kuma, Pooja A Chawl. Recent advances in the development of nitrogen-containing heterocyclic Anti-Alzheimer's agents. Current topics in medicinal chemistry. 2022-10-24. PMID:36278462. |
alzheimer's disease is usually triggered by numerous associated factors, including depleted amount of acetylcholine (ach), excessive aggregation of β-amyloid peptide (aβ), tau hyperphosphorylation with neurofibrillary tangle formation as well as deposition of feeble plaques in a specific portion of the brain (hippocampus and cortex). |
2022-10-24 |
2023-08-14 |
Not clear |
| E A Kovalenko, E V Makhnovich, N A Osinovskaya, A N Bogolepov. [Focused ultrasound as a non-invasive method with therapeutic potential in patients with Alzheimer's disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 122. issue 10. 2022-10-24. PMID:36279227. |
alzheimer's disease (ad) is a common, progressive neurodegenerative disease characterized by abnormal deposition of β-amyloid (aβ) and hyperphosphorylated tau protein. |
2022-10-24 |
2023-08-14 |
Not clear |
| Soumya Mukherjee, Celine Dubois, Keyla Perez, Shiji Varghese, Ian E Birchall, Miranda Leckey, Natalia Davydova, Catriona McLean, Rebecca M Nisbet, Blaine R Roberts, Qiao-Xin Li, Colin L Masters, Victor A Streltso. Quantitative proteomics of tau and Aβ in detergent fractions from Alzheimer's disease brains. Journal of neurochemistry. 2022-10-22. PMID:36271678. |
quantitative proteomics of tau and aβ in detergent fractions from alzheimer's disease brains. |
2022-10-22 |
2023-08-14 |
human |
| Soumya Mukherjee, Celine Dubois, Keyla Perez, Shiji Varghese, Ian E Birchall, Miranda Leckey, Natalia Davydova, Catriona McLean, Rebecca M Nisbet, Blaine R Roberts, Qiao-Xin Li, Colin L Masters, Victor A Streltso. Quantitative proteomics of tau and Aβ in detergent fractions from Alzheimer's disease brains. Journal of neurochemistry. 2022-10-22. PMID:36271678. |
the two hallmarks of alzheimer's disease (ad) are amyloid-β (aβ) plaques and neurofibrillary tangles marked by phosphorylated tau. |
2022-10-22 |
2023-08-14 |
human |